Thursday, October 19, 2017 1:06:05 PM
In any case, all the "other decisions" that could have been
made, that would have resulted in much higher pps by now,
those are impossible to evaluate, so a systematic rebuttal
is impossible.
All I'm saying is that Pluristem is like most other small biotechs,
it's a real challenge to guide it to the finish line, and I see
"backseat driving" as basically cheapshots at management.
But I certainly don't want to discourage anyone from expressing their
feelings here (but I do reserve the right to respond with a bit
of sarcasm every now and then).
All in all, let's face it, this company is potentially an absolutely
fabulous investment. If the technology works, it could be an
astounding success story, both commercially and in helping
patients.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM